Dihydroergotamine
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Dihydroergotamine
Dihydroergotamine: Known uses and market status in Canada
Summary
The TxGNN model’s candidates for Dihydroergotamine (score ≥ 0.99) are all known uses that can be traced to a source. There is therefore currently no new predicted indication for this drug in Canada.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (all traceable model candidates are known uses) |
| Known uses among model candidates | 0 |
| Evidence level | Not applicable |
| Canada Market Status | Marketed (marketed DINs: 2 of 2) |
| Number of DINs | 2 (marketed: 2) |
Known uses among the model’s candidates
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| none | none |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| none | none |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| none |
Canada Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 02228947 | MIGRANAL NASAL SPRAY 4MG/ML | Valid | |
| 00027243 | DIHYDROERGOTAMINE (DHE), 1MG/ML | Valid |
Safety Considerations
- Disease-level contraindication signals (from the TxGNN knowledge graph, not label text): hypertension and hypertensive disorders, liver failure, porphyria (inherited porphyria and porphyrin metabolism disease), coronary artery disease, Prinzmetal angina, and peripheral vascular disease (including peripheral arterial disease and intermittent claudication).
- Drug Interactions: 100 interactions were identified. Major interactions include isometheptene, epinephrine (including ophthalmic and topical forms), ephedrine (including nasal), clarithromycin, lorcaserin, fenfluramine and dexfenfluramine. Moderate interactions include doxycycline, tetracycline, aprepitant, dexamethasone, cimetidine, clotrimazole, miconazole, eluxadoline, glycerol phenylbutyrate and metreleptin. Only the first 20 are shown in the compiled data.
- Subtype-specific concern: as noted above, vasoconstriction may raise concern for posterior circulation ischemia in brainstem aura.
Please refer to the package insert for the full warnings and contraindications.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.